1
|
Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. Acta Neuropathol 2015; 129:895-907. [PMID: 25869641 PMCID: PMC4436700 DOI: 10.1007/s00401-015-1415-2] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Revised: 03/19/2015] [Accepted: 03/20/2015] [Indexed: 12/18/2022]
Abstract
Alzheimer’s disease (AD) is characterized by extracellular amyloid β (Aβ) deposition and intracellular tau aggregation. Many studies have indicated some association between these processes, but it remains unknown how the two pathologies are linked. In this study, we investigated whether expression of amyloid precursor protein (APP) influences extracellular seed-dependent intracellular tau accumulation in cultured cells. Treatment of tau-expressing SH-SY5Y cells with Aβ fibrils did not induce intracellular tau aggregation. On the other hand, in cells expressing both tau and APP, treatment with tau fibrils or Sarkosyl-insoluble tau from AD brains induced intracellular tau aggregation. The seed-dependent intracellular tau aggregation was not induced by expression of APP lacking the extracellular domain. The amount of phosphorylated tau aggregates in cultured cells was dose dependently elevated in response to increased levels of APP on the cell membrane. Our results indicate that the extracellular region of APP is involved in uptake of tau fibrils into cells, raising the possibility that APP, but not Aβ, influences cell-to-cell spreading of tau pathologies in AD by serving as a receptor of abnormal tau aggregates.
Collapse
|
2
|
Kume H, Kametani F. Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage. Biochem Biophys Res Commun 2006; 349:1356-60. [PMID: 16979587 DOI: 10.1016/j.bbrc.2006.08.181] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2006] [Accepted: 08/31/2006] [Indexed: 02/03/2023]
Abstract
The accumulation and deposition of fibrillar Abeta is thought to be the primary cause of Alzheimer's disease. Abeta is derived from Alzheimer amyloid precursor protein (APP) by sequential proteolytic cleavage involving beta- and gamma-secretase. Recently, gamma-secretase was shown to cleave near the cytoplasmic membrane boundary of APP (called the epsilon-cleavage), as well as in the middle of the membrane domain (gamma-cleavage). It has been reported that the C-terminus of Abeta is generated via a series of sequential cleavages, epsilon-cleavage followed by gamma-cleavage. However, recent article has reported that gamma- and epsilon-site cleavage are regulated independently. The relationship between gamma-site and epsilon-site cleavage is still unknown. In this study, we analyzed the generation of AICD and Abeta in CHO cells expressing APP derivatives. We found that epsilon-site cleavage preferentially occurs alpha-secretase processing product, and that Abeta 11-40/42 was generated without gamma-secretase epsilon-site cleavage, indicating that gamma-site cleavage and epsilon-site cleavage were regulated differentially.
Collapse
Affiliation(s)
- Hideaki Kume
- Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Tokyo 156-8585, Japan
| | | |
Collapse
|
3
|
Kametani F. Secretion of long Abeta-related peptides processed at epsilon-cleavage site is dependent on the alpha-secretase pre-cutting. FEBS Lett 2004; 570:73-6. [PMID: 15251442 DOI: 10.1016/j.febslet.2004.06.034] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2004] [Revised: 06/14/2004] [Accepted: 06/14/2004] [Indexed: 10/26/2022]
Abstract
Abeta is the major component of amyloid in the brain in Alzheimer's disease and is derived from Alzheimer amyloid precursor protein (APP) by sequential proteolytic cleavage involving alpha-, beta- and gamma-secretase. Recently, gamma-secretase was shown to cleave near the cytoplasmic membrane boundary of APP (called the epsilon-cleavage), as well as in the middle of the membrane domain (gamma-cleavage). However, the precise relationship between gamma- and epsilon-cleavage is still unknown. In this paper, I analyzed Abeta-related peptides using immunoprecipitation and liquid chromatography ion trap mass spectrometer and found some long Abeta-related peptides, starting at Abeta residues 16Lys-23Asp and ending at 43Thr-52Leu, in the culture media of COS-1 cells and in human brain extract. These results indicated that longer Abeta-related peptides cleaved at epsilon-cleavage site were secreted under normal conditions and were dependent on the alpha-secretase cleavage products.
Collapse
Affiliation(s)
- Fuyuki Kametani
- Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagayaku, Tokyo 156-8585, Japan.
| |
Collapse
|
4
|
Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003; 84:1215-36. [PMID: 12614323 DOI: 10.1046/j.1471-4159.2003.01615.x] [Citation(s) in RCA: 146] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Alzheimer's disease (AD) is the most commonly diagnosed form of dementia in the elderly. Predominantly this disease is sporadic in nature with only a small percentage of patients exhibiting a familial trait. Early-onset AD may be explained by single gene defects; however, most AD cases are late onset (> 65 years) and, although there is no known definite cause for this form of the disease, there are several known risk factors. Of these, the epsilon4 allele of the apolipoprotein E (apoE) gene (APOE) is a major risk factor. The epsilon4 allele of APOE is one of three (epsilon2 epsilon3 and epsilon4) common alleles generated by cysteine/arginine substitutions at two polymorphic sites. The possession of the epsilon 4 allele is recognized as the most common identifiable genetic risk factor for late-onset AD across most populations. Unlike the pathogenic mutations in the amyloid precursor or those in the presenilins, APOE epsilon4 alleles increase the risk for AD but do not guarantee disease, even when present in homozygosity. In addition to the cysteine/arginine polymorphisms at the epsilon2/epsilon3/epsilon4 locus, polymorphisms within the proximal promoter of the APOE gene may lead to increased apoE levels by altering transcription of the APOE gene. Here we review the genetic and biochemical evidence supporting the hypothesis that regulation of apoE protein levels may contribute to the risk of AD, distinct from the well known polymorphisms at the epsilon2/epsilon3/epsilon4 locus.
Collapse
Affiliation(s)
- Simon M Laws
- Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Neuroscience, University of Western Australia, Hollywood Private Hospital, Perth, Western Australia, Australia
| | | | | | | |
Collapse
|
5
|
Kim JH, Rah JC, Fraser SP, Chang KA, Djamgoz MBA, Suh YH. Carboxyl-terminal peptide of beta-amyloid precursor protein blocks inositol 1,4,5-trisphosphate-sensitive Ca2+ release in Xenopus laevis oocytes. J Biol Chem 2002; 277:20256-63. [PMID: 11927572 DOI: 10.1074/jbc.m108326200] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The effects of Alzheimer's disease-related amyloidogenic peptides on inositol 1,4,5-trisphosphate receptor-mediated Ca(2+) mobilization were examined in Xenopus laevis oocytes. Intracellular Ca(2+) was monitored by electrophysiological measurement of the endogenous Ca(2+)-activated Cl(-) current. Application of a hyperpolarizing pulse released intracellular Ca(2+) in oocytes primed by pre-injection of a non-metabolizable inositol 1,4,5-trisphosphate analogue. The carboxyl terminus of the amyloid precursor protein inhibited inositol 1,4,5-trisphosphate receptor-mediated intracellular Ca(2+) release in a dose-dependent manner. Equimolar beta-amyloid peptides Abeta(1-40) or Abeta(1-42) had no effect, and whereas a truncated carboxyl terminus lacking the Abeta domain was equipotent to the full-length one, a carboxyl terminus fragment lacking the NPTY sequence was less effective than the full-length fragment. The inhibition induced by the carboxyl terminus was not associated with the block of the Ca(2+)-dependent Cl(-) channel itself or compromised Ca(2+) influx. We conclude that the carboxyl terminus of the amyloid precursor protein inhibits inositol 1,4,5-trisphosphate-sensitive Ca(2+) release and could thus disrupt Ca(2+) homeostasis and that the carboxyl terminus is much more effective than the beta-amyloid fragments used. By perturbing the coupling of inositol 1,4,5-trisphosphate and Ca(2+) release, the carboxyl terminus of the amyloid precursor protein can potentially be involved in inducing the neural toxicity characteristic of Alzheimer's disease.
Collapse
Affiliation(s)
- Joung-Hun Kim
- Neurobiology Group, Department of Biology, Sir Alexander Fleming Bldg., Imperial College of Science, Technology and Medicine, London SW7 2AZ, United Kingdom
| | | | | | | | | | | |
Collapse
|
6
|
Choi SH, Park CH, Koo JW, Seo JH, Kim HS, Jeong SJ, Lee JH, Kim SS, Suh YH. Memory impairment and cholinergic dysfunction by centrally administered Abeta and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J 2001; 15:1816-8. [PMID: 11481240 DOI: 10.1096/fj.00-0859fje] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S H Choi
- Department of Pharmacology, College of Medicine, National Creative Research Initiative Centre for Alzheimer's Dementia and Neuroscience Research Institute, MRC, Seoul National University, Seoul 110-799, South Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Kametani F, Tanaka K, Usami M, Maruyama K, Mori H. Human wild presenilin-1 mimics the effect of the mutant presenilin-1 on the processing of Alzheimer's amyloid precursor protein in PC12D cells. J Neurol Sci 2001; 188:27-31. [PMID: 11489281 DOI: 10.1016/s0022-510x(01)00543-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Most familial early-onset Alzheimer's disease (FAD) is caused by mutations in the presenilin-1 (PS1) gene. Abeta 42 is derived from amyloid precursor protein (APP) and increased concentrations are widely believed to be a pathological hallmark of abnormal PS function. Thus, the interaction between PS1 and APP is central to the molecular mechanism of AD. To examine the effect of wild-type human PS1 on rat APP metabolism, we made several PC12D cell lines that expressed human wild or mutant PS1, and analyzed the processing of endogenous rat APP and the intracellular gamma-secretase activity. We found the ratio of Abeta 42/Abeta 40 increased in PC12D cells expressing wild-type human PS1. These changes were identical to those found in PC12D cells expressing human PS1 bearing the A260V mutation. These results suggest that APP metabolism is physiologically regulated by the PS1 and that loss of normal PS1 affects gamma-secretase activity.
Collapse
Affiliation(s)
- F Kametani
- Department of Molecular Biology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagayaku, 156-8585, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
8
|
Chong YH, Sung JH, Shin SA, Chung JH, Suh YH. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J Biol Chem 2001; 276:23511-7. [PMID: 11306564 DOI: 10.1074/jbc.m009466200] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
To explore the direct role of beta-amyloid (Abeta) and carboxyl-terminal fragments of amyloid precursor protein in the inflammatory processes possibly linked to neurodegeneration associated with Alzheimer's disease, the effects of the 105-amino acid carboxyl-terminal fragment (CT(105)) of amyloid precursor protein on the production of tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-9 (MMP-9) were examined in a human monocytic THP-1 cell line and compared with that of Abeta. CT(105) elicited a marked increase in TNF-alpha and MMP-9 production in the presence of interferon-gamma in a dose- and time-dependent manner. Similar patterns were obtained with Abeta despite its low magnitude of induction. Autocrine TNF-alpha is likely to be a main mediator of the induction of MMP-9 because the neutralizing antibody to TNF-alpha inhibits MMP-9 production. Genistein, a specific inhibitor of tyrosine kinase, dramatically diminished both TNF-alpha secretion and subsequent MMP-9 release in response to CT(105) or Abeta. Furthermore, PD98059 and SB202190, specific inhibitors of ERK or p38 MAPK respectively, efficiently suppressed CT(105)-induced effects whereas only PD98059 was effective at reducing Abeta-induced effects. Our results suggest that CT(105) in combination with interferon-gamma might serve as a more potent activator than Abeta in triggering inflammatory processes and that both tyrosine kinase and MAPK signaling pathways may represent potential therapeutic targets for the control of Alzheimer's disease progression.
Collapse
Affiliation(s)
- Y H Chong
- Departments of Microbiology and Ophthalmology, College of Medicine, Division of Molecular Biology and Neuroscience, Medical Research Center, Ewha Womans University, 911-1, Mok-6-dong, Yangcheonku, Seoul, 158-056, Korea.
| | | | | | | | | |
Collapse
|
9
|
Abstract
The amyloid precursor protein (APP) gene and its protein products have multiple functions in the central nervous system and fulfil criteria as neuractive peptides: presence, release and identity of action. There is increased understanding of the role of secretases (proteases) in the metabolism of APP and the production of its peptide fragments. The APP gene and its products have physiological roles in synaptic action, development of the brain, and in the response to stress and injury. These functions reveal the strategic importance of APP in the workings of the brain and point to its evolutionary significance.
Collapse
Affiliation(s)
- P K Panegyres
- Department of Neuropathology, Royal Perth Hospital, Western Australia.
| |
Collapse
|
10
|
Rah JC, Kim HS, Kim SS, Bach JH, Kim YS, Park CH, Seo JH, Jeong SJ, Suh YH. Effects of carboxyl-terminal fragment of Alzheimer's amyloid precursor protein and amyloid beta-peptide on the production of cytokines and nitric oxide in glial cells. FASEB J 2001; 15:1463-5. [PMID: 11387258 DOI: 10.1096/fj.00-0724fje] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J C Rah
- Department of Pharmacology, College of Medicine, National Creative Research Initiative Centre for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Centre, Seoul National University, Seoul 110-799, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Seo J, Kim S, Kim H, Park CH, Jeong S, Lee J, Choi SH, Chang K, Rah J, Koo J, Kim E, Suh Y. Effects of nicotine on APP secretion and Abeta- or CT(105)-induced toxicity. Biol Psychiatry 2001; 49:240-7. [PMID: 11230875 DOI: 10.1016/s0006-3223(00)01124-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Several lines of evidence indicated that overexpression or aberrant processing of amyloid precursor protein (APP) is causally related to Alzheimer's disease (AD). Amyloid precursor protein is principally cleaved within the amyloid beta protein domain to release a large soluble ectodomain (APPs), known to have a wide range of trophic functions. The central hypothesis guiding this review is that nicotine may play an important role in APP secretion and protection against toxicity induced by APP metabolic fragments (beta-amyloid [Abeta], carboxyl terminal [CT]). Findings from our experiments have shown that nicotine enhances the release of APPs, which has neurotrophic and neuroprotective activities in concentration-dependent (>50 micromol/L) and time-dependent (>2 hours) manners. In addition, pretreatment of nicotine (>10 micromol/L for 24 hours) partially prevented Abeta or CT(105)-induced cytotoxicity in primary cultured neuron cells, and the effects of nicotine-induced protection were inhibited by the pretreatment with a nicotine alpha-bungarotoxin. Nicotine (>10 micromol/L for 24 hours) partially inhibited CT(105)-induced cytotoxicity when PC12 cells was transfected with CT(105). From these results, we proposed that nicotine or nicotinic receptor agonist treatment might improve the cognitive functions not only by supplementation of cholinergic neurotransmission, but also by protecting Abeta- or CT(105)-induced neurotoxicity probably through the increased release of APPs and the activation of nicotinic receptors.
Collapse
Affiliation(s)
- J Seo
- Department of Pharmacology, College of Medicine, National Creative Research Initiative Centre for Alzheimer's Proteins and Neuroscience Research Institute, Medical Research Centre, Seoul National University, Seoul, South Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kim H, Park CH, Cha SH, Lee J, Lee S, Kim Y, Rah J, Jeong S, Suh Y. Carboxyl‐terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J 2000. [DOI: 10.1096/fj.99-0809com] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Hye‐Sun Kim
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| | - Cheol Hyoung Park
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| | - Seok Ho Cha
- Department of Pharmacology and ToxicologyKyorin UniversitySchool of MedicineMitakaTokyo181Japan
| | - Jun‐Ho Lee
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| | - Sangwon Lee
- Department of ChemistryCollege of Natural ScienceKonkuk UniversitySeoulKorea
| | - Yangmee Kim
- Department of ChemistryCollege of Natural ScienceKonkuk UniversitySeoulKorea
| | - Jong‐Cheol Rah
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| | - Sung‐Jin Jeong
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| | - Yoo‐Hun Suh
- Department of PharmacologyCollege of Medicine and Department of Molecular PharmacologyNeuroscience Research InstituteMRC Seoul National UniversityBiomedical Brain Research CenterNIHSeoul110‐799South Korea
| |
Collapse
|
13
|
Suh YH, Kim HS, Lee JP, Park CH, Jeong SJ, Kim SS, Rah JC, Seo JH, Kim SS. Roles of A beta and carboxyl terminal peptide fragments of amyloid precursor protein in Alzheimer disease. JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM 2000:65-82. [PMID: 11128614 DOI: 10.1007/978-3-7091-6284-2_6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/15/2023]
Abstract
Several lines of evidence indicate that A beta may play an important role in the pathogenesis of AD. However, there are several discrepancies between the production of A beta and the development of the disease. Thus, A beta may not be the sole active fragment of beta-amyloid precursor protein (betaAPP) in the neurotoxicity assiciated with AD. We focused on the amyloidegenic carboxyl terminal fragments of betaAPP containing the full length of A beta (CT105). We synthesized a recombinant carboxyl-terminal 105 amino acid fragment of betaAPP and examined the effects of CT105 and A beta on cultured neurons, Ca++ uptake into rat brain microsomes, Na+-Ca++ exchange activity, ion channel forming activity in lipid bilayers and passive avoidance performance of mice. Our results suggest that the cytotoxic and channel inducing effects of CT105 are much more potent than that of A beta and toxic mechanisms of CT105 are different from those of A beta. Taken together, these lines of evidence postulate that CT is an alternative toxic element important in the generation of the symptoms common to AD.
Collapse
Affiliation(s)
- Y H Suh
- Department of Pharmacology, College of Medicine and Neuroscience Research Institute, MRC, Seoul National University, Korea.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Fraser SP, Suh YH, Djamgoz MB. Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Trends Neurosci 1997; 20:67-72. [PMID: 9023874 DOI: 10.1016/s0166-2236(96)10079-5] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Alzheimer's disease is a progressive dementia characterized in part by deposition of proteinaceous plaques in various areas of the brain. The main plaque protein component is beta-amyloid, a metabolic product of the beta-amyloid precursor protein. Substantial evidence has implicated beta-amyloid (and other amyloidogenic fragments of the precursor protein) with the neurodegeneration observed in Alzheimer's disease. Recently, beta-amyloid precursor protein and its amyloidogenic metabolic fragments have been shown to alter cellular ionic activity, either through interaction with existing channels or by de novo channel formation. Such alteration in ionic homeostasis has also been linked with cellular toxicity and might provide a molecular mechanism underlying the neurodegeneration seen in Alzheimer's disease.
Collapse
Affiliation(s)
- S P Fraser
- Dept of Biology, Imperial College of Science, Technology and Medicine, London, UK
| | | | | |
Collapse
|
15
|
Tokuda T, Tanaka K, Kametani F, Ikeda S, Yanagisawa N. Secretory cleavage of beta-amyloid precursor protein in the cerebral white matter produces amyloidogenic carboxyl-terminal fragments. Neurosci Lett 1995; 186:149-52. [PMID: 7539900 DOI: 10.1016/0304-3940(95)11307-i] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
To elucidate the metabolic process generating amyloid-beta protein (A beta) from beta-amyloid precursor protein (APP) in human brain, we partially purified secretory forms and carboxyl-terminal fragments (CTFs) of APP from the white matter of a Down's syndrome brain. We obtained secretory forms of APP which lack the entire A beta sequence and CTFs which contain the full-length A beta from the cerebral white matter. Some A beta-lacking secretory APP isoforms in the white matter were derived from APP695. These results suggest that amyloidogenic CTFs can be produced by secretory cleavage of APP which is anterogradely transported through the axon in human brain.
Collapse
Affiliation(s)
- T Tokuda
- Department of Molecular Biology, Tokyo Institute of Psychiatry, Japan
| | | | | | | | | |
Collapse
|